First launches for UCB's anti-epileptic Vimpat
This article was originally published in Scrip
Executive Summary
UCBhas launched Vimpat (lacosamide), an anticonvulsant for treatment of adults with partial onset epilepsy in the UK, Germany and Austria following EU approval in September (Scrip Online, September 3rd, 2008). The launches are the first in the world. Vimpat can be administered via tablet, syrup or intravenously as an adjunctive therapy. In the UK, the daily cost of Vimpat is £5.15 for the 200mg tablet and £44.50 for an intravenous infusion.